Premium
Efficacy and safety of high‐dose cabergoline in Parkinson's disease
Author(s) -
Odin P.,
Oehlwein C.,
Storch A.,
Polzer U.,
Werner G.,
Renner R.,
Shing M.,
Ludolph A.,
Schüler P.
Publication year - 2006
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2005.00514.x
Subject(s) - cabergoline , medicine , hyperkinesia , parkinson's disease , adverse effect , dyskinesia , levodopa , anesthesia , disease , hormone , prolactin
Objectives – To assess the efficacy and safety of high‐dose (up to 20 mg/day) cabergoline in Parkinson's disease (PD) patients with motor fluctuations and/or dyskinesias. Materials and methods – Thirty‐four PD patients had cabergoline up‐titrated and their levodopa ( l ‐dopa) reduced over a maximum of 20 weeks, followed by at least 6 weeks steady cabergoline dosing. Primary endpoint was change in mean hyperkinesia intensity at the final visit (week 26). Results – Mean (± SD) cabergoline was increased from 6.43 ± 2.66 to 12.78 ± 5.67 mg/day and mean l ‐dopa reduced from 606.6 ± 263.9 to 370.6 ± 192.5 mg/day. A significant reduction ( P < 0.001) in mean hyperkinesia intensity occurred from baseline (day 0) to week 26. Improvements in ‘on with dyskinesias’, mean dystonia intensity ( P < 0.05), time spent in ‘severe off’ condition, severity of ‘off’ periods as well as clinical/patient global impression, and health‐related quality of life were observed. Twenty‐four drug‐related adverse events were recorded of which four were regarded as serious. Conclusion – High‐dose cabergoline was well tolerated and provided significant improvements in the Parkinson symptomatology and a reduced requirement for l ‐dopa.